Delivering precision oncology with cutting edge liquid biopsy technology
Lucence is a precision oncology company founded in 2016. Headquartered in Palo Alto and Singapore, Lucence delivers its services worldwide through twin United States CLIA-licensed laboratories. The company has raised over US$29 million in funding with the most recent Series A round in late 2019 led by IHH Healthcare, one of the world’s largest private healthcare networks together with SGInnovate and Heliconia Capital, a Temasek unit.
Dr Min-Han Tan, Founding CEO and Medical Director
Dr Tan is an academic medical oncologist by training and based in Palo Alto. He is internationally recognised for discovering the circulating tumour-endothelial clusters in early cancer. Dr Tan has won several international research awards from American Society of Clinical Oncology, European Society for Medical Oncology and Association of Southeast Asian Nations.
Dr Yukti Choudhury, Co-founder and CTO
Dr Choudhury created the world’s first personalised human stem cell model for cancer drug liver toxicity. She has several publications in peer-reviewed journals and patent filings for novel molecular assays. Dr Choudhury has won research awards from American Society of Clinical Oncology and the Kidney Cancer Association where she was named a “Promising Young Investigator”.
Dr Chao Xie, Chief Data Scientist
Dr Chao is the winner of the $1M Bioinformatics Algorithm Challenge organised by the Pentagon. He has worked at Craig Venter’s Human Longevity Inc on one of the world’s largest genomic datasets. Dr Chao previously led data science teams at Grab and AirAsia.
Mr Kevin Goh, CFO
Mr Goh is a chartered accountant with over 14 years’ experience in companies including KPMG and Econ Healthcare Group. He was previously the Group Financial Controller of a publicly listed healthcare company in Singapore. Mr Goh is a chess grandmaster and 7-time national chess champion of Singapore.